EMD Serono Joins Industry Leaders for The Economist Events' War On Cancer Forum in Boston
ROCKLAND, Mass., Sept. 29, 2015 /PRNewswire/ -- EMD Serono today announced that Merck KGaA, Darmstadt, Germany, is a platinum sponsor of The Economist Events' Health Care Forum: War on Cancer. The event brings together policymakers, oncology experts, researchers and pharmaceutical and insurance executives to engage in important dialogue on advancing cancer research and care through collaboration on September 29, 2015 in Boston.
"Over the last 10 years, the survival rates in many types of cancers as well as the number of potential oncology treatments in development have risen steadily, but cancer is a resilient enemy," said Paris Panayiotopoulos, President and Managing Director of EMD Serono. "The Economist Events' 'War on Cancer' Forum brings together key stakeholders with the goal of fostering collaboration and helping us identify new solutions that can one day benefit patients."
The American Cancer Society estimates that there will be more than 1.6 million new cancer cases diagnosed and nearly 590,000 cancer deaths in the U.S. this year. Five-year survival rates for many cancers are improving due, in part, to improved prevention, screening and therapy. However, there are still unmet needs, particularly in rare and difficult-to-treat cancers where there are fewer treatment options. The War on Cancer forum will explore which cancers are actually preventable, the importance of big data and the role that technology presents in altering people's behaviors for improved health, among other topics.
The Economist Events' War on Cancer forum is part of a global event series, the first of which took place in Hong Kong in March, with the final conference to be held in London in October. The Boston event will be chaired by The Economist's healthcare correspondent Natasha Loder.
For more information, click here. Join the conversation and connect with speakers and attendees on Twitter via #WarOnCancer.
About EMD Serono
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is a leading U.S. biopharma company focused exclusively on specialty care. For more than 40 years, EMD Serono has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.
For more information, please visit www.emdserono.com.
Merck KGaA, Darmstadt, Germany
Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
Cory Tromblee
Phone: 781.681.2393
SOURCE EMD Serono
Share this article